 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Feb 08, 2012 |
| Title |
Gene expression response to acrylamide in rat pups |
| Organism |
Rattus norvegicus |
| Experiment type |
Expression profiling by array
|
| Summary |
Acrylamide is a type-2 alkene monomer with established human neurotoxic effects. While the primary source of human exposure to acrylamide is occupational, other exposure sources include food, drinking water, and smoking. In this study, neurobehavioral assays coupled with transcriptional profiling analysis were conducted to assess both behavioral and gene expression effects induced by acrylamide neurotoxicity in rats when administered during early postnatal life. Acrylamide administration in rat pups induced significant characteristic neurotoxic symptoms including increased heel splay, decrease in grip strength, and decrease in locomotor activity. Transcriptome analysis with the Affymetrix Rat Genome 230 2.0 array indicated that acrylamide treatment caused a significant alteration in the expression of genes involved in muscle contraction, pain regulation, and dopaminergic neuronal pathways. First, in agreement with the observed behavioral effects, expression of the Mylpf gene involved in muscle contraction was downregulated in the spinal cord in response to acrylamide. Second, in sciatic nerves, acrylamide repressed the expression of the opioid receptor gene Oprk1 that is known to play a role in neuropathic pain regulation. Finally, in the cerebellum, acrylamide treatment caused a decrease in the expression of the nuclear receptor gene Nr4a2 that is required for development of dopaminergic neurons. Thus, our work examining the effect of acrylamide at the whole-genome level on a developmental mammalian model has identified novel genes previously not implicated in acrylamide neurotoxicity that can be further developed into biomarkers for assessing the risk of acrylamide exposure.
|
| |
|
| Overall design |
Three-week-old male Wistar rat pups were treated with either acrylamide or saline daily (30 mg/kg) for 21 days, then tissues (cerebellum, spinal cord, and sciatic nerve) were harvested and frozen. Two biological replicate samples, each sample consisting of pooled tissue from 2 rats, were analyzed for each treatment.
|
| |
|
| Contributor(s) |
Agarwal AK |
| Citation(s) |
22197712 |
| Submission date |
May 02, 2011 |
| Last update date |
Jul 31, 2017 |
| Contact name |
Ameeta Agarwal |
| E-mail(s) |
aagarwal@olemiss.edu
|
| Phone |
662-915-1218
|
| Organization name |
University of Mississippi
|
| Department |
National Center for Natural Products Research
|
| Street address |
NCNPR, Room 2049
|
| City |
University |
| State/province |
MS |
| ZIP/Postal code |
38677 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL1355 |
[Rat230_2] Affymetrix Rat Genome 230 2.0 Array |
|
| Samples (12)
|
| GSM718689 |
Cerebellum, saline control, biological rep1 |
| GSM718690 |
Cerebellum, saline control, biological rep2 |
| GSM718691 |
Cerebellum, acrylamide treated, biological rep1 |
| GSM718692 |
Cerebellum, acrylamide treated, biological rep2 |
| GSM718693 |
Spinal cord, saline control, biological rep1 |
| GSM718694 |
Spinal cord, saline control, biological rep2 |
| GSM718695 |
Spinal cord, acrylamide treated, biological rep1 |
| GSM718696 |
Spinal cord, acrylamide treated, biological rep2 |
| GSM718697 |
Sciatic nerve, saline control, biological rep1 |
| GSM718698 |
Sciatic nerve, saline control, biological rep2 |
| GSM718699 |
Sciatic nerve, acrylamide treated, biological rep1 |
| GSM718700 |
Sciatic nerve, acrylamide treated, biological rep2 |
|
| Relations |
| BioProject |
PRJNA140443 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE29004_RAW.tar |
33.3 Mb |
(http)(custom) |
TAR (of CEL, CHP) |
| Processed data included within Sample table |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...